Why Merck's 32% Rally Isn't Enough to Change the Bearish View

Merck shares have risen 32.3% over the past three months and are trading above their 50- and 200-day SMAs, but the company remains highly dependent on Keytruda, which generated $23.3 billion in sales in the first nine months of 2025 (up 8% YoY) and accounts for over 50% of pharmaceutical revenue. Offsetting positives—FDA approval of Keytruda Qlex, strong launches for Capvaxive and Winrevair, and pipeline expansion plus acquisitions (Cidara $9.2bn, Verona ~ $10bn)—are a 40% drop in Gardasil sales YTD driven by China weakness, a decline in 2026 EPS estimates from $9.23 to $7.94 over 60 days, and Keytruda’s loss of exclusivity in 2028, leaving a mixed risk/reward profile for investors.

Analysis

Market structure: Merck (MRK) retains near-term pricing power from Keytruda (50%+ pharma sales) and new assets (Capvaxive, Winrevair, Ohtuvayre), so oncology and cardio-pulmonary incumbents (MRK, PFE, AZN partners) are winners; Gardasil weakness hurts Merck/partner Zhifei and China-facing vaccine suppliers through channel destocking. Competitive dynamics: emergence of dual PD‑1/VEGF agents (SMMT/ivonescimab, Pfizer’s SSGJ‑707) creates meaningful share risk in NSCLC before 2028 LOE, pressuring ASPs and margins if they become standard of care within 12–36 months. Supply/demand: temporary oversupply in China for HPV implies demand rebound risk (inventory drawdown timeline 3–9 months) while Keytruda LOE in 2028 signals longer-term demand elasticity and potential price erosion of 20–40% vs branded pricing if biosimilars enter. Cross-asset: MRK strength compresses credit spreads modestly (IG pharma), equity vols should fall; increased M&A spending raises short-term leverage—watch 10y treasury sensitivity as big M&A costs hit cash flow, and USD/FX exposure from China slows FY26 revenue timing.

Risk assessment: Tail risks include earlier-than-expected biosimilar/biosimilar interchangeability (pre-2028 court loss or settlement), failed Phase III readouts for key in‑house combos, or a prolonged China vaccine demand slump that pushes Gardasil revenues down >50% in FY26. Time horizons: immediate (days–weeks) volatility around quarterly prints and April 2026 FDA HIV decision; short-term (3–12 months) driven by Gardasil channel normalization and integration costs from Verona/Cidara; long-term (2028+) dominated by Keytruda LOE/patent outcomes and commercial launches. Hidden dependencies: Merck’s revenue trajectory depends on successful integration of acquisitions and commercial execution in China/Japan; combos with Moderna and partner trial outcomes are binary. Catalysts to watch: Apr 2026 FDA HIV decision, EU RSV review, Q1–Q3 2026 Keytruda growth cadence, any patent litigations through 2027.

Trade implications: Direct play—establish a measured long MRK core position (2–3% portfolio) funded by trimming overvalued large-cap biotech exposure; add to 4–5% if April 2026 FDA wins or Keytruda YoY revenue stays ≥7% in two consecutive quarters. Options—buy a protective structure: long-dated (Jan 2028) call LEAPs sized 25% of intended equity exposure and concurrently purchase a Jan 2028 40/60 put spread (cost-limited hedge) to cap LOE tail risk; consider selling 30–60 day covered calls to finance premium if IV>20%. Pair trade—go long MRK and short LLY (equal notional 1–2% portfolio) to capture valuation gap (MRK forward P/E ~13 vs peers >25) ahead of FY26 realignment. Sector rotation—underweight China-dependent vaccine names and overweight oncology/respiratory franchise plays (MRK, PFE, selected diversified pharma) over next 6–18 months.

Contrarian angles: Consensus underestimates the protective value of Keytruda Qlex SC patents and the revenue runway they buy—SC IP could push meaningful branded share retention beyond 2028, reducing downside to estimates by ~10–20% if litigations hold. Market may be overpricing near-term M&A EPS drag; historically (Pfizer post‑Lipitor era) aggressive M&A plus strong launches can re-rate a lower‑PE pharma within 18–36 months. Conversely, downside is under-appreciated if dual PD‑1/VEGF agents gain rapid global traction—this single clinical shift could remove 10–30% of Keytruda addressable market within 2–4 years. Unintended consequence: heavy M&A increases integration execution risk that could still compress FY26–27 EPS by the recent analyst downgrade magnitude (~14% from $9.23 to $7.94).

Key Decisions for Investors

• Establish a phased long MRK equity position equal to 2–3% of portfolio now (buy 50% today, 50% on any >3% pullback) and increase to 4–5% if April 2026 FDA approval for the doravirine/islatravir fixed-dose combo or if Keytruda revenue growth sustains ≥7% YoY for two consecutive quarters.
• Implement an options hedge: buy Jan 2028 MRK call LEAPs sized to 25% of intended equity exposure and purchase a Jan 2028 40/60 put spread (cost-limited) for downside protection against LOE; fund premium by selling 30–60 day covered calls when IV>20%.
• Execute a pair trade: go long MRK and short LLY in equal notional amounts (1–2% portfolio each) to exploit valuation dispersion (MRK forward P/E ~13 vs LLY >25); close or rebalance after April 2026 FDA outcome or if the spread compresses by 30%.
• Reduce/underweight exposure to vaccine names with >20% China revenue by 40–60% over the next 3 months (due to channel destocking risk); redeploy proceeds into MRK and diversified oncology/respiratory franchises (PFE, selected IG names) with 6–18 month horizon.